vTv Therapeutics Q4 net loss widens on higher expenses

Reuters03-11
vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss widens on higher expenses

Overview

  • US diabetes drug developer's Q4 net loss widened on higher R&D and G&A expenses

  • Company reported no revenue for Q4 2025

  • Cash position strengthened by $20 mln upfront payment from Newsoara and private placement financing

Outlook

  • vTv expects to complete CATT1 Phase 3 trial enrollment in Q3 2026

  • Company says funding runway extends well past anticipated CATT1 Phase 3 topline readout

Result Drivers

  • HIGHER R&D SPENDING - Co said increased R&D expenses were mainly due to higher spending on cadisegliatin clinical studies

  • HIGHER G&A COSTS - Co attributed increased G&A expenses to higher payroll, legal, and share-based costs

  • The Company’s cash position as of December 31, 2025, was $88.9 million compared to $36.7 million as of December 31, 2024

Company press release: ID:nGNX8Hff61

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

-$0.58

Q4 Operating Expenses

$7.89 mln

Q4 Operating Income

-$7.89 mln

Q4 Pretax Profit

-$7.14 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for vTv Therapeutics Inc is $49.00, about 34.2% above its March 9 closing price of $36.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment